We advised the sales agent on the offering

Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market program by Coherus Oncology, Inc. of shares of its common stock for up to an aggregate offering price of $50 million. The common stock is listed on the Nasdaq Global Market under the symbol “CHRS.”

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI(R) (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Jared Madnick and Alexis Aguila Johnson. Partner David R. Bauer and associate Ryan Grawe provided intellectual property advice. Counsel Ziyuan (Constance) Zhang and associate Alex (Ang) Gao provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post